Based on OHSU research, FDA approves drug that reduces hearing loss in pediatric cancer patients
January 30, 2023
An OPB segment highlights the recent FDA approval of sodium thiosulfate, a drug studied for years by OHSU researchers that prevents treatment-induced hearing loss in pediatric cancer patients who receive the common chemotherapy drug Cisplatin. The segment includes insight from Kristin Knight, M.S., and Jennifer Boesche, whose child received cancer therapy at the hospital.